GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus

GT Biopharma Inc shares on the Nasdaq Capital Market eased modestly on 05/29/2026, with the United States-based micro-cap biotech stock changing hands at around USD 0.67 during the session, according to TradingView data as of that date, leaving the company with a market capitalization of roughly USD 2.4 million after a weaker week for the name.TradingView as of 05/29/2026

The oncology-focused developer remains listed on Nasdaq under the ticker GTBP and headquartered in the United States, giving it exposure to one of the world’s most liquid biotech markets even as its share price continues to fluctuate in a low single-digit dollar range for U.S. retail investors.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

GT Biopharma Inc: core business model

GT Biopharma Inc concentrates on developing immuno-oncology therapies that harness the body’s own immune system to target cancer cells, aiming to generate future revenue primarily from potential product approvals, partnering deals, and milestone or royalty income tied to its pipeline.

Valuation metrics and multiples for GT Biopharma Inc

With the stock around USD 0.67 and an indicated market capitalization near USD 2.4 million on 05/29/2026, GT Biopharma Inc currently sits at the extreme micro-cap end of the U.S. biotech universe, where traditional valuation measures such as price-to-earnings or EV/EBITDA are less meaningful given the company’s development-stage profile and lack of recurring commercial revenue.TradingView as of 05/29/2026

In this segment of the Nasdaq market, investors often focus more on cash runway, clinical milestones and potential partnering optionality than on conventional valuation metrics, so GT Biopharma Inc’s small equity value and volatile share price tend to be interpreted against its research pipeline and funding prospects rather than near-term earnings power.

Conclusion

The latest trading on 05/29/2026 leaves GT Biopharma Inc positioned as a low-priced U.S. Nasdaq biotech equity with a market value of only a few million dollars, underscoring how sensitive the stock can be to changes in liquidity and sentiment.

Against that backdrop, traditional valuation ratios play a limited role while investors instead tend to weigh the price level and market capitalization against the company’s early-stage oncology pipeline, financing options and broader biotech risk appetite on U.S. markets.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.